Navigation Links
FDA Approves Arcapta Neohaler to Treat Chronic Obstructive Pulmonary Disease
Date:7/1/2011

SILVER SPRING, Md., July 1, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Arcapta Neohaler (indacaterol inhalation powder) for the long term, once-daily maintenance bronchodilator treatment of airflow obstruction in people with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

COPD is a serious lung disease that makes breathing difficult. Symptoms can include breathlessness, chronic cough and excessive phlegm. Cigarette smoking is the leading cause of COPD, and is the fourth leading cause of death in the United States, according to the Centers for Disease Control and Prevention.

Arcapta Neohaler is a new molecular entity in the beta2-adrenergic agonist class that helps muscles around the airways of the lungs stay relaxed to prevent symptoms of COPD, such as wheezing and breathlessness. Arcapta Neohaler is not intended to treat asthma or sudden, severe symptoms of COPD.

"The approval of new long-term drugs for COPD that relieve breathing difficulty by opening airways provides another treatment option for the millions of people," said Curtis Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA's Center for Drug Evaluation and Research.

The safety and efficacy of Arcapta Neohaler was demonstrated in six confirmatory clinical trials that included 5,474 patients ages 40 and older with a clinical diagnosis of COPD. Those treated had a smoking history of at least one pack a day for 10 years and exhibited moderate-to-severe decreases in lung function.

Arcapta Neohaler carries a boxed warning that long-acting beta2 adrenergic agonists (LABA) increase the risk of asthma-related death. All LABA, including Arcapta Neohaler, should not be used in patients with asthma, unless used with a long-term asthma control medication.

The FDA approved Arcapta Neohaler with a medication guide that includes instructions for use and information about the potential risks of taking the drug. The most common side effects reported by those using Arcapta Neohaler include runny nose, cough, sore throat, headache and nausea.  

Arcapta Neohaler is marketed by Novartis Pharmaceuticals Corp. of East Hanover, N.J.

For more information:

National Heart, Lung, and Blood Institute: Chronic Obstructive Pulmonary Disease
http://www.nhlbi.nih.gov/health/dci/Diseases/Copd/Copd_WhatIs.html

Approved Drugs: Questions and Answers
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm

Media Inquiries: Morgan Liscinsky, 301-796-0397, morgan.liscinsky@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FDA Approves XARELTO® (rivaroxaban tablets) to Help Prevent Deep Vein Thrombosis in Patients Undergoing Knee or Hip Replacement Surgery
2. FDA Approves Lazanda® - First Fentanyl Nasal Spray - for the Management of Breakthrough Pain in Cancer Patients
3. FDA Approves First Generic Versions of the Antibiotic Levofloxacin to Treat Certain Infections
4. FDA Approves Nulojix for Kidney Transplant Patients
5. FDA Approves New Test To Help Determine if Breast Cancer Patients Are Candidates for Herceptin Treatment
6. FDA Approves First Ceramic-on-Metal Total Hip Replacement System
7. FDA Approves Redesigned Labels for Some Merck Drugs
8. FDA Approves Updates to Lillys Humalog® (insulin lispro injection [rDNA origin]) Label
9. FDA Approves Marketing of RMS Subcutaneous Needle Sets
10. FDA Approves Injectable Gel to Treat Fecal Incontinence
11. FDA approves Incivek for hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Ill. , Dec. 5, 2016 For ... score on the 2017 Human Rights Campaign Foundation,s ... The CEI is a national benchmarking tool used to ... bisexual, and transgender (LGBT) employee equality. For ... Survey to help companies gauge their equality efforts, culture ...
(Date:12/5/2016)... , Dec. 5, 2016 Eisai Inc. ... at the 2016 Annual Meeting of the American Epilepsy ... CIII, is indicated as an adjunctive therapy for the ... secondarily generalized seizures and primary generalized tonic-clonic seizures (PGTC) ... age and older. Please see Important Safety Information for ...
(Date:12/5/2016)... , Dec. 5, 2016  Seno Medical Instruments, Inc., ... a new tool to improve the process of diagnosing ... from its European MAESTRO post-market surveillance and clinical follow-up ... Symposium (SABCS) taking place from December 6-10, 2016 ... San Antonio, Texas . Seno ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... The Lymphoma Research Foundation ... research and serving the lymphoma community through a comprehensive series of education programs, ... Event in New York City, with long-time partners The Paul Foundation, on November ...
(Date:12/4/2016)... ... , ... While James Earl Jones is known for myriad roles on stage ... "Front Page". One of the forthcoming episodes examines mammogram techniques; a very important part ... part due to early detection. Like any other disease, treatments have a much higher ...
(Date:12/4/2016)... ... December 03, 2016 , ... Penrose Senior Care Auditors® was ... Tuesday evening at the 26th Annual SMU Cox Dallas 100™ Awards Ceremony and ... Institute for Entrepreneurship. Dallas 100™, co-founded by the Caruth Institute, honors the ingenuity, ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish to gain ... of a cosmetic procedure known as Carbon Dioxide (C02) Fractional Laser Resurfacing ... age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity or textural ...
(Date:12/4/2016)... , ... December 04, 2016 , ... Responsible dental care ... must brush properly to achieve optimal results. This important necessity inspired an inventor from ... for a way to ensure that people break or avoid bad techniques of brushing ...
Breaking Medicine News(10 mins):